Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results